A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

Q: What is the clinical evidence from this study?

Population: Acute coronary syndrome (n=1000). Intervention: Ticagrelor vs. Standard 90 mg twice daily vs 60 mg twice daily. Primary outcome: Steady-state minimum concentration (Cmin,ss) and pharmacokinetic parameters.

Q: What does this research mean for the field?

In acute coronary syndrome, elderly patients and smokers receiving ticagrelor 90 mg twice daily frequently exceed the upper safety threshold, whereas a 60 mg twice-daily regimen maintains exposure within the target therapeutic range. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Ji Woo Lim; H C Kim; Heungjo Kim; H Lee; Kyongkuk Ryu; Min Jung Chang

doi:10.1038/s41598-026-62066-5

July 13, 2026Scientific ReportsOpen Access

A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

View Full Paper

Ask AI

Bookmark

Share

Key result

Simulated ticagrelor 60 mg maintains target exposure in elderly and smokers whereas 90 mg exceeds thresholds.

n=1,000

Why the study?

Optimal ticagrelor dosing is crucial for preventing bleeding and thrombosis in ACS, requiring characterization of population pharmacokinetics using pooled data.

Does a reduced ticagrelor dose of 60 mg twice daily maintain therapeutic plasma concentrations while avoiding supratherapeutic exposure compared to 90 mg twice daily in specific ACS patient subgroups?

Key Points

To develop an integrated population pharmacokinetic model of ticagrelor and its active metabolite using pooled data to assess exposure across patient subgroups with acute coronary syndrome.
Generated virtual cohorts totaling 1,000 individuals derived from two published population pharmacokinetic studies of acute coronary syndrome patients receiving 60 mg or 90 mg twice daily.
Constructed a one-compartment model incorporating parent–metabolite kinetics with covariates including age, sex, body weight, and smoking status.
Evaluated model stability and precision using 1,000 bootstrap samples, goodness-of-fit diagnostics, and visual predictive checks across dosing regimens.
The final model estimated ticagrelor absorption rate constant at 0.613 h⁻¹, oral clearance at 13.3 L/h, and apparent volume of distribution at 228 L, while the active metabolite AR-C124910XX showed oral clearance of 9.75 L/h and apparent volume of distribution of 4.59 L.
Covariate modeling identified reduced ticagrelor clearance with older age and smoking status (approximately 11% reduction in smokers), whereas metabolite clearance was higher in smokers and lower in females.
Simulations of the 90 mg twice-daily regimen showed 35–40% of elderly smokers exceeded the upper safety threshold (Cmin, ss > 360 ng/mL), whereas a 60 mg twice-daily dose maintained concentrations within the target window (180–360 ng/mL).

Structured PICO

Does a reduced ticagrelor dose of 60 mg twice daily maintain therapeutic plasma concentrations while avoiding supratherapeutic exposure compared to 90 mg twice daily in specific ACS patient subgroups?

P

Population

1,000 virtual patients with acute coronary syndrome, generated from published pharmacokinetic models, simulated over 144 hours to evaluate ticagrelor dosing regimens.

I

Intervention

Simulated ticagrelor dosing regimens: 180 mg loading dose followed by 60 mg or 90 mg twice daily (BID) maintenance doses over 144 hours.

C

Comparator

Comparison across different dosing regimens (60 mg vs 90 mg BID) and patient subgroups (age, smoking status).

O

Outcome

Pharmacokinetic parameters (Ka, CL/F, Vd/F) and simulated steady-state plasma concentrations (Cmin,ss) compared to a target therapeutic range of 180-360 ng/mL.surrogate

Pharmacokinetic simulations suggest that reducing ticagrelor maintenance dosing to 60 mg twice daily may prevent supratherapeutic exposure and reduce bleeding risk in elderly patients and smokers with ACS.

Limitations

Relies on data obtained from published literature, which may introduce inherent biases and variability
Absence of direct pharmacodynamic measurements in synthetic cohorts limits ability to model individual variability in platelet response
Covariate selection was limited to those consistently reported across identified source studies
Exposure thresholds have inherent uncertainties as they were derived from PK-PD modeling rather than direct ischemic outcome data
Relies entirely on synthetic data, precluding de novo covariate building or identification of novel sources of variability
Moderate-to-substantial interindividual variability limits precision of population-level predictions for individual dose titration
Findings are model-informed and hypothesis-generating rather than clinically validated evidence and require prospective validation
Observed association between smoking and reduced clearance may reflect model-driven effects rather than direct mechanistic evidence

Implication

May warrant ticagrelor dose reduction in elderly smokers with ACS; leaves open prospective outcome trials.

Abstract

Ticagrelor is a P2Y12 inhibitor used to reduce thrombotic events in acute coronary syndrome (ACS). Optimal dosing is crucial for preventing bleeding and thrombosis; therefore, we developed the population pharmacokinetics (PK) of ticagrelor by incorporating results from previous population PK studies. Studies were identified through a PubMed search, and an integrated PK model was developed using pooled synthetic datasets. Two published PK models generated virtual cohorts of 1,000 individuals each with covariates of age, sex, weight, and smoking status. A one-compartment model with a parent–metabolite relationship was used to describe ticagrelor and its active metabolite. The final model estimated ticagrelor Ka at 0.613 h⁻¹, oral clearance (CL/F) at 13.3 L/h and apparent volume of distribution (Vd/F) of 228 L; the metabolite showed oral clearance (CLM/F) of 9.75 L/h and apparent volume of distribution (VM/F) of 4.59 L. Simulations showed that elderly patients and smokers receiving 90 mg twice-daily frequently exceeded the upper safety threshold (Cmin, ss > 360 ng/mL), whereas a 60 mg twice-daily regimen maintained exposure within the target therapeutic range (180–360 ng/mL). These hypothesis-generating findings warrant prospective validation in diverse ACS populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2026) studied Acute coronary syndrome (n=1,000). Ticagrelor vs. Standard 90 mg twice daily vs 60 mg twice daily was evaluated on Steady-state minimum concentration (Cmin,ss) and pharmacokinetic parameters. Simulations demonstrated that elderly patients and smokers receiving ticagrelor 90 mg twice-daily frequently exceeded the upper safety threshold, whereas 60 mg twice-daily maintained target exposure.

synapsesocial.com/papers/6a5600ff10535b590d162469 https://doi.org/10.1038/s41598-026-62066-5

View Full Paper

Ask AI

Bookmark

Share

A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading